TAAR1 and schizophrenia: In addition to these developments, the current landscape of novel mechanisms of action includes TAAR-1 agonism, muscarinic receptor agonism, serotonin receptor antagonism/inverse agonism, and glutamatergic modulation, offering targeted treatments for cognitive and negative symptoms of schizophrenia.